From Daphne Dumbrille (COO) and Jacquie Badiou (President), HAE Canada:
At the 2022 HAEi Global Leadership Workshop in Frankfurt, Germany, HAE Canada proudly presented a poster titled “HAE with normal C1 esterase inhibitor (HAEnC1INH): Diagnosis, treatment and attack frequency from the 2020 Canadian patient survey”. We are grateful to have been invited and appreciate the opportunity to share our poster with fellow participants. Thank you, HAEi Team, for organizing this incredible workshop. We are bursting with knowledge and excited to put it to practical use back in Canada.
Speaking of posters, our abstract titled “HAE with normal C1 esterase inhibitor (HAEnC1INH): Treatment and attack frequency changes from 2017 to 2020 based on data from the Canadian national patient surveys” was accepted by the Canadian Society of Allergy and Clinical Immunology (CSACI) and presented during the poster session at their 2022 Annual Scientific Meeting in September in Quebec City. Thank you to Dr. Suzanne Kelly of Red Maple Trials for producing these abstracts and posters, and thank you also to all authors for contributing both time and expertise.
In November 2022, we will host our first Hybrid Patient Information Update. From Hamilton, Ontario, we will welcome local patients and caregivers, and members from across Canada will join us virtually. We look forward to seeing members in person, and we are excited that our members will once again be able to connect in person with one another. After the Update, members will be encouraged to remain to attend the HAE Canada 2022 Annual General Meeting.
We look forward to a busy fall connecting with members in person.
